

1 **Antemortem vs. postmortem histopathological and ultrastructural findings in paired**
2 **transbronchial biopsies and lung autopsy samples from three patients with confirmed**
3 **SARS-CoV-2 infection**

4 **Gagiannis D^{1*}, Umatham VG^{2*}, Bloch W³, Rother C⁴, Stahl M¹, Witte HM^{2,4,5}, Djudjaj S⁶, Boor P⁶, Steinestel K²**

5 ¹Department of Pulmonology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany;

6 ²Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg

7 40, Germany; ³Department of Molecular and Cellular Sport Medicine, German Sport University Cologne, 50933

8 Cologne, Am Sportpark Müngersdorf 6, Germany; ⁴Department of Hematology and Oncology,

9 Bundeswehrkrankenhaus Ulm, 89081 Ulm, Oberer Eselsberg 40, Germany; ⁵Department of Hematology and

10 Oncology, University Hospital Schleswig-Holstein Campus Luebeck, 23552 Luebeck, Ratzeburger Allee 160,

11 Germany; ⁶Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, Pauwelsstrasse 30,

12 Germany.

13 ***Shared first authorship.**

14

15 **Corresponding author:**

16 **Konrad Steinestel, MD PhD**

17 Institute of Pathology and Molecular Pathology

18 Bundeswehrkrankenhaus Ulm

19 Oberer Eselsberg 40

20 89081 Ulm, Germany

21 T: 0049 731 1710 2400

22 F: 0049 731 1710 2403

23 konradsteinestel@bundeswehr.org

24

25

26

27

28 **Funding:** This work was in part supported by the German Registry of COVID-19 Autopsies

29 (www.DeRegCOVID.ukaachen.de), funded by the Federal Ministry of Health (ZMVI1-2520COR201), and the

30 Federal Ministry of Education and Research within the framework of the network of university medicine

31 (DEFEAT PANDEMIcs, 01KX2021)

32 **Declaration of interest:** DG and KS were speakers for Boehringer-Ingelheim. All other authors declare no

33 conflict of interest.

34

35

36 **ABSTRACT**

37 Background: Acute respiratory distress syndrome (ARDS) is the major cause of death in coronavirus disease
38 2019 (COVID-19). Multiple autopsy-based reports of COVID-19 lung pathology describe diffuse alveolar damage
39 (DAD), organizing pneumonia (OP) and fibrotic change, but data on early pathological changes as well as during
40 progression of the disease are rare.

41 Research question: Comparison of histopathological and ultrastructural findings in paired transbronchial
42 biopsies (TBBs) and autopsy material from three patients with confirmed SARS-CoV-2-infection.

43 Methods: We prospectively enrolled 3 patients with confirmed SARS-CoV-2 infection. Full clinical evaluation
44 was performed including high-resolution computed tomography (HR-CT). We took TBBs at different time points
45 during the disease and autopsy tissue samples after the patients' death.

46 Results: SARS-CoV-2 was detected by RT-PCR and/or FISH in all TBBs. Lung histology revealed pneumocyte
47 hyperplasia and capillary congestion in one patient who died short after hospital admission with detectable
48 virus in 1/2 autopsy samples from the lung. SARS-CoV-2 was detected in 2/2 autopsy samples from a patient
49 with a fulminant course of the disease and very short latency between biopsy and autopsy, both showing
50 widespread DAD. In a third patient with a prolonged course, i.e. five weeks of ICU treatment with ECMO,
51 autopsy samples showed extensive interstitial fibrosis without detectable virus by RT-PCR and/or FISH.

52 Interpretation: We report the course of COVID-19 in paired TBB and autopsy samples from three patients at an
53 early stage, in rapidly progressive and in a prolonged disease course. Our findings illustrate vascular, organizing
54 and fibrotic patterns of COVID-19-induced lung injury and suggest an early spread of SARS-CoV-2 from the
55 upper airways to the lung periphery with diminishing viral load during disease.

56

57 **RUNNING TITLE**

58 Lung pathology during COVID-19

59 **KEYWORDS**

60 COVID-19, SARS-CoV-2, ARDS, lung pathology, diffuse alveolar damage, organizing pneumonia, lung fibrosis

61

62 Since SARS-CoV-2 and the resulting disease, COVID-19, emerged in late 2019, much effort has been put in a
63 better understanding of the clinical course of the disease. While most patients present with a rather mild
64 symptoms, some patients – especially those sharing risk factors such as older age, cardiovascular disease or
65 chronic obstructive pulmonary disease (COPD) – are at risk of developing life-threatening respiratory failure¹.

66 Early autopsy studies conducted in China described diffuse alveolar damage (DAD) with an early edematous
67 phase followed by hyaline membrane formation, desquamation of pneumocytes and an increased interstitial
68 mononuclear infiltrate². In one case, Tian et al. report loose intra-alveolar fibromyxoid proliferation reminiscent
69 of organizing pneumonia (OP)³. In the meantime, it is widely accepted that COVID-19 follows a biphasic pattern
70 of an initial viral response phase followed by an inflammatory second phase, and that mortality is linked
71 primarily to the development of acute respiratory distress syndrome (ARDS)^{1,4}. Based on a meta-analysis of 131
72 reported autopsy cases, Polak et al. postulated that the main histologic patterns of COVID-19-related lung

73 injury can be categorized into epithelial (reactive changes and DAD), vascular (microvascular damage, thrombi
74 and OP) and fibrotic⁵, however these patterns may overlap and be coexistent in the same patient at a given
75 time point. Nicholson et al. proposed that an initial (pre-)exudative phase of DAD (0-7 days) is followed by an
76 organizing phase (1 week to months) and might ultimately progress to fibrosis (months)⁶. The exact
77 mechanisms of SARS-CoV-2-related ARDS development are not fully understood. It has been postulated that
78 severity of COVID-19 might correlate with a hyper-inflammatory response and uncontrolled secretion of
79 cytokines, showing similarities to cytokine releasing syndrome (CRS)⁷; however, it has been shown that
80 cytokine levels in severe cases of COVID-19 are lower compared to severe influenza patients⁸. Our own group
81 demonstrated overlapping clinical, serological, and imaging features between severe COVID-19 and lung
82 manifestation of autoimmune disease such as systemic lupus erythematosus (SLE) or systemic sclerosis⁹. In our
83 study, the presence of autoantibodies (antinuclear antibodies and extractable nuclear antibodies, ANA/ENA)
84 was significantly associated with a need for intensive care treatment and the occurrence of severe
85 complications. This finding has now been confirmed by others and might be attributed to extrafollicular B cell
86 activation with excessive production of antibody-secreting cells (ASCs) in critically ill COVID-19 patients¹⁰⁻¹². A
87 better understanding of the pathophysiology of lung injury in COVID-19 would also shed light on the urgent
88 question of long-term sequelae of the disease in millions of COVID-19 survivors. Despite a large number of
89 autopsy studies which represent a snapshot of the disease at the time of death, to the best of our knowledge,
90 there is so far no study comparing *antemortem* vs. *postmortem* histopathological and ultrastructural features
91 of COVID-19. We report here the histopathology of transbronchial biopsies and autopsy material together with
92 RT-PCR- and FISH-based detection of SARS-CoV-2 and ultrastructural analyses from three patients with
93 confirmed SARS-CoV-2 infection.

94 **METHODS**

95 We consecutively included three (n=3) patients with positive SARS-CoV-2-RT-PCR (mucosal swab) admitted to
96 the Bundeswehrkrankenhaus (German Armed Forces Hospital) Ulm in March and April 2020 after obtaining
97 informed consent. Patients or their relatives had given written informed consent to routine diagnostic
98 procedures (serology, bronchoscopy, radiology) as well as (partial) autopsy in the case of death, respectively, as
99 well as to the scientific use of data and tissue samples in the present study. This project was approved by the
100 local ethics committee of the University of Ulm (ref. no. 129-20) and conducted in accordance with the
101 Declaration of Helsinki.

102 **Clinical characteristics**

104 We collected clinical information from electronic patient files. Data included disease-related events, preexisting
105 comorbidities, imaging, and clinical follow-up. Baseline clinical characteristics are given in **Table 1**. The “Berlin
106 definition” was used to categorize ARDS.¹³ The Horowitz quotient ($\text{PaO}_2/\text{FiO}_2$) was assessed in all ARDS cases
107 based on arterial blood gas analysis. During ICU treatment, ventilation parameters, duration of invasive
108 ventilation, catecholamine support, prone positioning, Murray lung injury score and the need for additional
109 temporary dialysis were continuously assessed¹⁴. A profitable trial of prone positioning was defined by an

110 increasing Horovitz quotient of 30 mmHg or more. One entire trial covered 16 hours of sustained prone
111 positioning.

112 **Serology/Laboratory values**

113 Laboratory values upon admission to ICU included D-dimers, lactate dehydrogenase (LDH), interleukin-6 (IL-6)
114 and C-reactive protein (CRP) (**Table 1**). ANA/ANCA/ENA screening was performed as previously described⁹.

115 **Imaging**

116 Imaging was performed on a Somatom Force Scanner (Dual Source Scanner 2*192 slices, Siemens, Erlangen,
117 Germany) in accordance with the guidelines of the German Radiological Society and our hospital's COVID-19
118 guidelines, using low-dose CT (computed tomography) with high-pitch technology.¹⁵ The following parameters
119 were used: Tube voltage: 100kV with tin filtering, tube current: 96 mAs with tube current modulation. In two
120 cases examination was performed as a non-contrast enhanced full-dose protocol because of suspected ILD, in
121 one case as a contrast-enhanced CT scan to exclude pulmonary thromboembolism. X-ray examinations were
122 performed at the respective wards as bed-side X-ray examinations (Mobilett Mira Max, Siemens, Erlangen,
123 Germany) as a single anterior-posterior view. The CT images were evaluated according to the Expert Consensus
124 Statement of the RSNA and classified as typical, indeterminate, atypical and negative appearance for COVID-
125 19.^{15 16}

126 **Histology and SARS-CoV-2 detection**

127 Lung tissue specimens were obtained as transbronchial biopsies. In three deceased patients, partial autopsies
128 were performed in which lung (central and peripheral areas), heart and liver tissue were sampled extensively.
129 Specimens were stained with haematoxylin-eosin (HE), Phosphotungstic-Acid-Hematoxylin (PTAH), Elastica-
130 van-Gieson (EvG) and Masson-Goldner (MG). For SARS-Cov-2 fluorescence in situ hybridization (FISH)
131 Paraformaldehyde-fixed, paraffin-embedded 1µm sections of transbronchial biopsies (TBBs) and lung autopsy
132 material were deparaffinized followed by dehydration with 100% ethanol. FISH was performed with
133 the RNAscope® Multiplex Fluorescent Reagent Kit v2 assay (Advanced Cell Diagnostics, Inc.) according to the
134 manufacturer's instruction. Briefly, a heat-induced target retrieval step followed by protease was
135 performed. Afterwards sections were incubated with the following RNAscope® Probe -V-nCoV2019-S (#848561-
136 C1), -V-nCoV2019-S-sense (#845701-C1), -Hs-ACE2-C2 (#848151-C2) and -Hs-TMPRSS2-C2 (#470341-C2). After
137 the amplifier steps the fluorophores Opal™ 570 and 650 (PerkinElmer Life and Analytical
138 Sciences) were applied to the tissues incubated with C1 and C2 probe, respectively. Finally, nuclei
139 were stained with DAPI and the slides were mounted with ProLong™ Gold antifade
140 reagent (Invitrogen). Section were analyzed with Zeiss Axio Imager 2 and image analysis software (ZEN 3.0 blue
141 edition). SARS-CoV-2 RNA was extracted using Maxwell® 16 FFPE Plus Tissue LEV DNA Purification KIT
142 (Promega) on Maxwell® 16 IVD Instrument (Promega). Using TaqMan® 2019-nCoV kit (ThermoFisher),
143 detection of SARS-CoV-2 E-gene was performed according to the manufacturer's instructions.

144

145 **Electron microscopy**

146 Lung tissue was immersion-fixed with 4% paraformaldehyde in 0.1M PBS, pH 7.4. After several washing steps in
147 0.1M PBS, tissue was osmicated with 1% OsO₄ in 0.1 M cacodylate and dehydrated in increasing ethanol
148 concentrations. Epon infiltration and flat embedding were performed following standard procedures.
149 Methylene blue was used to stain semithin sections of 0.5 μm. Seventy to ninety-nanometer-thick sections
150 were cut with an Ultracut UCT ultramicrotome (Fa. Reichert) and stained with 1% aqueous uranyl acetate and
151 lead citrate. Samples were studied with a Zeiss EM 109 electron microscope (Fa. Zeiss) coupled to a TRS USB
152 (2048x2048, v.596.0/466.0) camera system with ImageSP ver.1.2.6.11 (x64) software

153 **RESULTS**

154 **Baseline patient characteristics and clinical course of the disease**

155 The study included two male and one female patient who were hospitalized for RT-PCR confirmed SARS-CoV-2
156 infection at the Bundeswehrkrankenhaus Ulm, Germany. The timeline of disease course is depicted in **Fig. 1 A**.
157 Baseline laboratory values and clinical characteristics are summarized in **Table 1**. Of note, ANA screening was
158 positive in all three patients; in patient #3, a specific autoantibody (Sci-70) could be detected by immunoblot.
159 While patients #1 and #3 had to undergo invasive ventilation 2 and 3 days after the diagnosis of COVID-19,
160 patient #2 was transferred from another hospital in a critical state. In patient #1, TBB was performed before
161 knowledge of a positive SARS-CoV-2 test result (day 0). This patient died from pulmonary thromboembolism 5
162 days later. Except for the continuation of a treatment protocol with hydroxychloroquine and azithromycin that
163 had been established in the previous hospital for patient #2, no specific therapeutic regimens were
164 administered to patients #1 and #3. TBBs in patient #2 and #3 were performed after 13 and 23 days of ICU
165 treatment, respectively, to assess the fibrotic change of lung parenchyma and to evaluate a possible use for
166 antifibrotic treatment options. An Autopsy was performed in all three cases on the day after the patients'
167 death following the published guidelines¹⁷.

168 **Imaging**

169 Representative CT scans from all patients are shown in **Fig. 1 B**. While there was a discrete NSIP-like pattern
170 with only minimal ground-glass opacities (GGO) in patient #1, patient #2 showed far more widespread GGOs
171 combined with consolidations and a positive aerobronchogram, suggestive of OP. In patient #3, imaging
172 showed severe parenchymal damage with diffuse GGOs, bronchiectasis, cyst formation and air trapping.

173 **Histopathologic findings in vital transbronchial biopsies (TBB) and lung autopsy samples**

174 The main finding in TBBs from patient #1 was reactive changes of pneumocytes (multinucleated cells,
175 "Napoleon hat sign") together with a discrete interstitial mononuclear infiltrate. In some alveoli, there was
176 accumulation of fibrin without hyaline membrane formation (**Fig. 1 C**). Autopsy samples from the same patient
177 showed focal capillary congestion together with microthrombosis and very few fibromyxoid plugs in the
178 alveolar lumen. TBBs from patient #2 - who was already mechanically ventilated at the time of biopsy - showed
179 alveolar collapse with entrapment of fibrin as well as reactive changes in few pneumocytes. Autopsy samples

180 from the same patient showed widespread fibromyxoid plugging with entrapment of ball-like fibrin and only
181 very few residual ventilated alveoli. In some alveoli, there was a shedding of reactive pneumocytes. In patient
182 #3, TBBs showed extensive OP with only very sparse interstitial inflammation. There was extensive interstitial
183 fibrosis and pseudo-honeycombing in autopsy samples from patient #3 with the formation of subepithelial
184 fibroblast foci.

185 **SARS-CoV-2 testing on tissue samples and SARS-CoV-2/ACE2/TMPRSS2-FISH**

186 RT-PCR analyses from tissue samples detected SARS-CoV-2 in TBBs from all three patients and in both autopsy
187 samples from patient #2 (Fig. 1 D). SARS-CoV-2 testing from autopsy samples revealed positivity in one out of
188 two samples in patient #1, while both autopsy samples were negative in patient #3. In line with that, SARS-CoV-
189 2 could be detected by FISH in TBBs, but not in autopsy samples from patients #1 and #3 (Fig. 2 A-B and E-F).
190 The virus was detected in airway epithelial cells but not in pneumocytes in patient #1. SARS-CoV-2 was
191 detected in both TBBs and autopsy samples from patient #2 (Fig. 2 C-D). There was only a weak and focal signal
192 for angiotensin converting enzyme-2 (ACE2) in all investigated samples (Fig. 2 A''-F''), while the signal for
193 transmembrane protease serine subtype 2 (TMPRSS2) was strongly detectable in all TBBs and autopsy samples
194 from patient #2, correlating with the presence of SARS-CoV-2 (Fig. 2 A'''-F''')

195 **Ultrastructural findings in lung autopsy samples**

196 Electron microscopy (EM) was performed on autopsy samples from all three patients. There was capillary
197 congestion with erythrocytes and fragmentocytes in patient #1. Of note, we observed long and thin
198 cytoplasmic protrusions of erythrocytes consistent with acanthocytosis. There was only minimal collagen
199 deposition in the interstitium (Fig. 3 A and B). In patient #2, there was widespread desquamation of alveolar
200 epithelium, interstitial edema and deposition of loosely organized collagen in the interstitium (Fig. 3 C). There
201 was extensive extracellular matrix deposition containing collagen and elastic fibrils in patient #3 (Fig. 3 D).
202 Moreover, we found luminal extension of endothelial protrusions consistent with intussusceptive (splitting)
203 angiogenesis (Fig. 3 E).

204 **DISCUSSION**

205 In the current paper, we report on antemortem and postmortem pathology in three patients with confirmed
206 SARS-CoV-2 infection including severe courses of COVID-19. From a clinical viewpoint, all three patients shared
207 established risk factors for a severe disease course (middle or advanced age, cardiovascular risk factors/disease
208 and/or history of smoking)¹⁸. Laboratory findings at the point of ICU admission showed elevated levels for LDH,
209 D-dimers, IL-6, and CRP, in line with published data¹⁹. Of note, two of the three patients (patients #2 and #3)
210 were positive for autoantibodies (ANA titers $\geq 1:320$ and/or positive ENA immunoblot). Previously, our group
211 showed that detection of autoantibodies is associated with a need for intensive care (ICU) treatment and the
212 occurrence of severe complications in COVID-19⁹. Since all patients were treated in the spring of 2020, no
213 immunosuppressive agents (dexamethasone) had been administered.

214 Histopathologic findings in lung biopsies from living COVID-19 patients have rarely been reported. A very early
215 report described oedema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy

216 inflammation, and multinucleated giant cells in two patients who underwent lobectomy for lung cancer and
217 who were retrospectively found to have COVID-19 at the time of operation³. We observed similar changes in
218 patient #1 who was also not yet known to have COVID-19 at the time of biopsy, indicating that pneumocyte
219 hyperplasia with proteinaceous exudate represents the earliest response to SARS-CoV-2 infection. The virus
220 was detected by RT-PCR and FISH while the latter method demonstrated SARS-CoV-2 in bronchiolar epithelium
221 where it was co-expressed with TMPRSS2, but not ACE2. This is in line with data from the literature showing
222 that TMPRSS2-expressing cells are highly susceptible to SARS-CoV-2 infection and TMPRSS2 expression might
223 correlate with age, sex and smoking habits^{20 21}. We observed low ACE2 expression in airway epithelial cells in
224 patient #1, consistent with previous reports²².

225 Only 1 of 2 autopsy samples from patient #1 tested positive for SARS-CoV-2 in RT-PCR, and characteristic
226 histopathological changes were very focal, supporting the assumption that the patient died early during the
227 disease before widespread involvement of the lung. Such intrapulmonary heterogeneity of SARS-CoV-2
228 infection has previously been described²³. Since the cause of death was pulmonary thromboembolism with
229 high D-dimer levels (>30 mg/l, ref. ≤0.5 mg/l), it is very interesting that electron microscopy showed capillary
230 congestion with erythrocytes and fragmentocytes in this patient. Endothelial inflammation and activation of
231 coagulation are associated with multiorgan failure and increased mortality, and antithrombotic drugs have
232 been proposed as potential therapies to prevent thrombosis in COVID-19²⁴. Given these findings, we think that
233 patient #1 might represent the vascular pattern of COVID-19-associated lung injury which has been shown to
234 occur early in the course of the disease⁵ and that these patients might profit from anti-coagulative therapy at
235 an early time point.

236 While patient #1 represents an early phase of the host response to SARS-CoV-2 infection, both TBBs and
237 autopsy samples from patient #2 showed widespread DAD with ball-like-fibrin and fibromyxoid plugging. This
238 acute fibrinous and organizing pneumonia (AFOP)-like pattern has previously been reported in response to
239 SARS-CoV-2 infection, and is believed to represent an intermediate form of lung injury between exudative DAD
240 and OP^{6 25}. In line with that, we think that the pattern of lung injury we observed in this patient represents the
241 climax of lung injury in response to SARS-CoV-2 infection, and the virus could be detected in all samples from
242 this patient by RT-PCR and FISH, respectively. TMPRSS2, but not ACE2, was highly expressed in both respiratory
243 epithelium and pneumocytes in TBBs and autopsy samples. It has to be noted that the uniformity of the
244 histologic findings might reflect the short time span between TBB and autopsy (48h) in this patient.
245 Ultrastructural analyses revealed the deposition of collagen fibrils in the interstitium, predicting the
246 development of interstitial fibrosis. While we know now that the application of corticosteroids would be
247 beneficial for patients with SARS-CoV-2 induced organizing lung damage, it is unclear whether such treatment
248 would also prevent the development of fibrosis. In patient #3, TBBs on day 23 showed extensive organizing
249 pneumonia and only sparse inflammation, while autopsy samples after the patient's death on day 42 showed
250 extensive interstitial fibrosis and microscopic honeycombing. The virus was still detectable in TBBs, but no virus
251 could be detected by RT-PCR and FISH in autopsy samples. Ultrastructural analyses confirmed extensive
252 collagen deposition. These findings support previous reports describing long-term follow-up of severe COVID-
253 19 and underline the potential of the development of interstitial fibrosis²⁶. Interestingly, in our previous study,
254 5/6 specific autoantibodies in patients with severe COVID-19 were associated with some form of sclerosing

255 CTD, raising the question if a pro-fibrotic (auto)immune response contributes to the development of lung
256 fibrosis in COVID-19 patients⁹. EM further confirmed the presence of intravascular endothelial protrusions
257 consistent with intussusceptive (splitting) angiogenesis as reported before²⁷.

258 INTERPRETATION

259 Taken together, we show here antemortem and postmortem biopsies from three patients with severe COVID-
260 19, illustrating histopathological changes during the disease (Fig. 4). Early changes include pneumocyte
261 hyperplasia and capillary congestion, which may be a sign of the risk of thromboembolic complications,
262 especially when high D-dimers are present. At this point, the virus has not necessarily spread throughout the
263 lung. The climax of lung injury is widespread DAD with or without organization, possibly including intermediate
264 AFOP-like patterns; at this point, virus is present in the airways and the lung. When this phase is survived, there
265 is increasing honeycomb-like fibrosis, however, viral load decreases over time and SARS-CoV-2 may not be
266 detected in late-stage disease. Development of lung fibrosis as a long-term consequence of COVID-19 is
267 associated with high morbidity and mortality and should definitely be circumvented whenever possible, raising
268 the question of a possible use of anti-fibrotic therapies, such as pirfenidone, in survivors of severe COVID-19.

269

270 ACKNOWLEDGEMENTS

271 The authors would like to thank all patients and their families for their consent to the use of data and images in
272 the present study. We further thank Carsten Hackenbroch, MD, for providing imaging data. The authors are
273 grateful for the outstanding quality of care of COVID-19 patients provided by the team of the intensive care
274 unit (ICU) at the Bundeswehrkrankenhaus Ulm.

275

276 AUTHOR CONTRIBUTIONS

277 Study concept: DG, VGU and KS. Data collection: DG, VGU, WB, CR, MS, HMW, SD, PB, KS. Sample collection:
278 DG, VGU, WB. Initial draft of manuscript: KS. Critical revision and approval of final version: all authors.

279

280 REFERENCES

- 281 1. Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of SARS-CoV-2.
282 *bmj* 2020;371
- 283 2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory
284 distress syndrome. *Lancet Respir Med* 2020;8(4):420-22. doi: 10.1016/S2213-2600(20)30076-
285 X [published Online First: 2020/02/23]
- 286 3. Tian S, Hu W, Niu L, et al. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19)
287 Pneumonia in Two Patients With Lung Cancer. *J Thorac Oncol* 2020;15(5):700-04. doi:
288 10.1016/j.jtho.2020.02.010 [published Online First: 2020/03/03]
- 289 4. Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional
290 autopsy cohort from Italy and New York City. *Modern Pathology* 2020;33(11):2156-68.
- 291 5. Polak SB, Van Gool IC, Cohen D, et al. A systematic review of pathological findings in COVID-19: a
292 pathophysiological timeline and possible mechanisms of disease progression. *Modern*
293 *Pathology* 2020;33(11):2128-38.
- 294 6. Nicholson AG, Osborn M, Devaraj A, et al. COVID-19 related lung pathology: old patterns in new
295 clothing? *Histopathology* 2020;77(2):169.
- 296 7. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020;368(6490):473-
297 74.

- 298 8. Mudd PA, Crawford JC, Turner JS, et al. Distinct inflammatory profiles distinguish COVID-19 from
299 influenza with limited contributions from cytokine storm. *Science Advances* 2020:eabe3024.
- 300 9. Gagiannis D, Steinestel J, Hackenbroch C, et al. Clinical, Serological, and Histopathological
301 Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-
302 Associated Interstitial Lung Disease (CTD-ILD). *Frontiers in immunology* 2020;11:2600.
- 303 10. Woodruff M, Ramonell R, Cashman K, et al. Critically ill SARS-CoV-2 patients display lupus-like
304 hallmarks of extrafollicular B cell activation. *medRxiv* 2020:2020.04.29.20083717. doi:
305 10.1101/2020.04.29.20083717 [published Online First: 2020/06/09]
- 306 11. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to systemic
307 autoimmune rheumatic diseases in severely ill patients with COVID-19. *Annals of the*
308 *Rheumatic Diseases* 2020;79(12):1661-63.
- 309 12. Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can
310 autoantibodies be useful? *Clinical and Translational Science* 2020
- 311 13. Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale,
312 justification, and supplementary material. *Intensive Care Med* 2012;38(10):1573-82. doi:
313 10.1007/s00134-012-2682-1 [published Online First: 2012/08/29]
- 314 14. Murray JF, Matthay MA, Luce JM, et al. An expanded definition of the adult respiratory distress
315 syndrome. *Am Rev Respir Dis* 1988;138(3):720-3. doi: 10.1164/ajrccm/138.3.720 [published
316 Online First: 1988/09/01]
- 317 15. SARS-CoV-2/COVID-19: Empfehlungen für die Radiologische Versorgung–Eine Stellungnahme, der
318 Deutschen Röntgengesellschaft (DRG), der Deutschen Gesellschaft für Neuroradiologie
319 (DGNR), der Gesellschaft für Pädiatrische Radiologie (GPR), der Deutschen Gesellschaft für
320 Interventionelle Radiologie (DeGIR), des Berufsverbands der Neuroradiologen (BDNR), und
321 des Berufsverbands der Radiologen (BDR). *RöFo-Fortschritte auf dem Gebiet der*
322 *Röntgenstrahlen und der bildgebenden Verfahren*; 2020. © Georg Thieme Verlag KG.
- 323 16. Simpson S, Kay FU, Abbara S, et al. Radiological Society of North America Expert Consensus
324 Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of
325 Thoracic Radiology, the American College of Radiology, and RSNA - Secondary Publication. *J*
326 *Thorac Imaging* 2020;35(4):219-27. doi: 10.1097/RTI.0000000000000524 [published Online
327 First: 2020/04/24]
- 328 17. Hanley B, Lucas SB, Youd E, et al. Autopsy in suspected COVID-19 cases. *Journal of clinical*
329 *pathology* 2020;73(5):239-42.
- 330 18. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019
331 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center
332 for Disease Control and Prevention. *Jama* 2020
- 333 19. Zhang Z-L, Hou Y-L, Li D-T, et al. Laboratory findings of COVID-19: a systematic review and meta-
334 analysis. *Scandinavian journal of clinical and laboratory investigation* 2020:1-7.
- 335 20. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing
336 cells. *Proceedings of the National Academy of Sciences* 2020;117(13):7001-03.
- 337 21. Piva F, Sabanovic B, Cecati M, et al. Expression and co-expression analyses of TMPRSS2, a key
338 element in COVID-19. *European Journal of Clinical Microbiology & Infectious Diseases* 2020:1-
339 5.
- 340 22. Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, thereceptor of SARS-
341 CoV-2. *Biorxiv* 2020
- 342 23. Desai N, Neyaz A, Szabolcs A, et al. Temporal and spatial heterogeneity of host response to SARS-
343 CoV-2 pulmonary infection. *Nature communications* 2020;11(1):6319. doi: 10.1038/s41467-
344 020-20139-7 [published Online First: 2020/12/11]
- 345 24. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro) thrombosis in COVID-19 and its
346 therapeutic implications. *Circulation research* 2020;127(4):571-87.
- 347 25. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European
348 Respiratory Society statement: update of the international multidisciplinary classification of
349 the idiopathic interstitial pneumonias. *American journal of respiratory and critical care*
350 *medicine* 2013;188(6):733-48.

- 351 26. Aesif SW, Bribriaco AC, Yadav R, et al. Pulmonary Pathology of COVID-19 Following 8 Weeks to 4
352 Months of Severe Disease: A Report of Three Cases, Including One With Bilateral Lung
353 Transplantation. *Am J Clin Pathol* 2020 doi: 10.1093/ajcp/aqaa264 [published Online First:
354 2020/12/15]
- 355 27. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis,
356 and Angiogenesis in Covid-19. *N Engl J Med* 2020;383(2):120-28. doi:
357 10.1056/NEJMoa2015432 [published Online First: 2020/05/22]

358

359 Figure Legends

360 **Figure 1. A, Timeline of the disease course in three COVID-19 patients.** While patients #1 and #3
361 were treated in the peripheral ward (green) after diagnosis (blue), patient #2 was taken over from
362 another hospital while immediate intubation (I) was required. Periods in the intensive care unit (ICU)
363 ranged from four to 39 days (orange). Transbronchial biopsies (B) were taken on the day of hospital
364 admission (patient 1), day 14 (patient 2) and day 23 (patient 3). Autopsies (A) were performed one
365 day after death in all 3 patients. **B, Results from imaging.** Imaging in patient# 1 showed an NSIP-like
366 pattern with minimal ground-glass-opacities (GGOs) in the left subpleural space. In patient# 2, there
367 were diffuse GGOs and both subpleural and peribronchial consolidations with a positive
368 aerobronchogram resembling organizing pneumonia. Imaging in patient #3 showed parenchymal
369 lung injury with diffuse GGOs, bronchiectasis, cysts, and air-trapping. **C, Representative histology
370 and CT imaging.** TBBs in patient #1 showed reactive pneumocyte changes (“Napoleon hat sign”) and
371 loose fibromyxoid plugging with capillary congestion in autopsy samples; in patient #2, TBBs showed
372 alveolar collapse with fibrin deposition and plug-like fibromyxoid organization (AFOP-like pattern) in
373 autopsy samples. TBBs from patient #3 showed condensed fibromyxoid plugging of alveoli, while
374 autopsy samples show interstitial collagen deposition and pseudo-honeycombing. *Scale bar in all
375 images: 100µm.* **D, Results from SARS-CoV-2 testing by RT-PCR.** While transbronchial biopsies (TBB)
376 were positive in all patients, 1/2 and 2/2 lung autopsy samples were positive in patients #1 and #2,
377 respectively. All autopsy samples were SARS-CoV-2-negative in patient #3.

378 **Figure 2. Fluorescence in situ hybridization (FISH) of SARS-Cov-2.** H&E staining and two
379 combinations of FISH that target SARS-CoV-2 S gene+ Angiotensin-converting enzyme
380 2 (ACE2) and replicative SARS-CoV-2-S gene sense + Transmembrane protease, serine
381 2 (TMPRSS2) have been performed on consecutive slides. SARS-CoV-2 (green, A''-F'') is strongly
382 expressed in the respiratory epithelium as shown in the biopsy of patient #1 (arrows in A'') and 2
383 (arrows in C'') and the autopsy of patient #2 (arrows in D''). To a lower extent virus could be detected
384 in alveolar epithelial cells as shown in the biopsy of patient #3 (arrow E''). High viral replication is
385 detectable in patient #2 as visualized with the V-nCoV2019-S sense probe (green, C''' and D'''). The
386 receptor TMPRSS2 is strongly expressed, mainly in the respiratory epithelium similar to the virus
387 (red, A'''-F''') much stronger than ACE2 (red, third A''-F''), whereas ACE2 is only weakly expressed.

388 **Figure 3. Ultrastructural analyses.** **A,** Alveolar capillaries are filled with erythrocytes and
389 fragmentocytes (asterisks) embedded in an alveolar septum with slightly increased extracellular
390 matrix accumulation. *Original magnification: 4000x, image width: 23,5µm.* **B,** Capillaries are filled
391 with erythrocytes and fragmentocytes (asterisks). The erythrocytes are altered in shape and form
392 very long and thin cytoplasmic processes as a hint of a special kind of acanthocytosis (arrows).
393 *Original magnification: 3000x, image width: 31,5µm.* **C,** Alveolar septum with erythrocytes and
394 leucocyte-filled capillaries is enlarged by interstitial fluid accumulation and loosely organized fibrillar
395 (arrows) and non-fibrillar extracellular matrix (arrowheads). The septum is bounded by alveolar
396 basement membrane with sheared off alveolar epithelium. *Original magnification: 3000x, image*

397 *width: 31,5µm. D, Interstitial fibrosis of a thickened alveolar septum with fibroblast debris (asterisks)*
 398 *and an adjacent alveolar epithelial cell (A). The extracellular matrix contains collagen fibrils, elastin*
 399 *and an accumulation of basement membrane material. Original magnification: 3000x, image width:*
 400 *31,5µm. E, The alveolar capillary endothelium reveals cytoplasmic processes with the formation of an*
 401 *interendothelial contact (arrow). The cytoplasmic process divides the lumen as a sign of*
 402 *intussusceptive (splitting) angiogenesis. Original magnification: 20000x, image width: 5,9µm.*

403 **Figure 4. Schematic model for the course of COVID-19 and possible implications for long-term**
 404 **sequelae in the lung.** While SARS-CoV-2 viral load decreases over time, an increasing and
 405 dysregulated (auto-)inflammatory response exerts deleterious effects on lung function and implies
 406 the risk for development of progressive interstitial fibrosis. The different stages in disease
 407 progression are reflected by the observed changes in patients 1-3.


408 **Table 1. Clinical characteristics of COVID-19 patients**

Characteristics	Patient #1	Patient #2	Patient #3
Age			
years	80s	60s	50s
Sex			
male/female	m	f	m
Preexisting diseases			
Cardiovascular risk factors ¹	x	x	x
Cardiovascular disease ²	x	x	-
Oncological disease	x	-	-
Rheumatic disease	-	x	-
Smoking history (pack years)	x (40)	-	x (40)
Lactate dehydrogenase, LDH (ref.)			
U/l (≤240)	292	449	414
D-Dimers (ref.)			
mg/l (≤0.5)	>30	3.65	0.92
C-reactive protein, CRP (ref.)			
mg/dl (≤0.5)	42.1	25.2	5.6
IL-6 (ref.)			
pg/ml (≤10)	2205	646	2093
ANA/ENA (ref.)			
ANA titer (IIF, <1:100)	1:100	1:1000	1:100
ENA (IB, neg.)	-	-	x (Scl-70)

ANA, antinuclear antibodies; ENA, extractable nuclear antigen; IB, immunoblot; IIF, indirect immunofluorescence; ¹diabetes mellitus, dyslipidemia, arterial hypertension, obesity, nicotine abuse; ²coronary disease, post-myocardial infarction, peripheral arterial vaso-occlusive disease, post-stroke, atherosclerosis.

Figure 1


A



B



C



D

ID	Pat #1	Pat #2	Pat #3
Transbronchial Biopsy (TBB)	+	+	+
Autopsy Sample 1	+	+	-
Autopsy Sample 2	-	+	-

Figure 2




Figure 3








Figure 4

